Bristol's Celgene buyout 'more important' given drug pricing pressure, CEO says

The drug pricing debate is raging on in Washington, D.C., and that's part of the reason Bristol-Myers Squibb wants to nab Celgene, CEO Giovanni Caforio told analysts Thursday.